Disc Medicine, Inc. Increase (Decrease) in Accrued Liabilities
Disc Medicine, Inc. (IRON) reported Increase (Decrease) in Accrued Liabilities of $671.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2024-05-09
- Disc Medicine, Inc. increase (decrease) in accrued liabilities for the quarter ending 2024-03-31 was $671.00K.
- Disc Medicine, Inc. increase (decrease) in accrued liabilities for the quarter ending 2023-12-31 was $2.73M, a 38.04% increase year-over-year.
- Disc Medicine, Inc. increase (decrease) in accrued liabilities for the quarter ending 2023-09-30 was $1.27M, a 184.38% increase year-over-year.
- Disc Medicine, Inc. increase (decrease) in accrued liabilities for the quarter ending 2023-06-30 was $93.00K.
- Disc Medicine, Inc. increase (decrease) in accrued liabilities for fiscal 2023 was $2.01M, a 33.69% increase from fiscal 2022.
- Disc Medicine, Inc. increase (decrease) in accrued liabilities for fiscal 2022 was $1.50M, a 2.59% decline from fiscal 2021.
- Disc Medicine, Inc. increase (decrease) in accrued liabilities for fiscal 2021 was $1.54M.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2024-03-31 | $671.00K 10-Q · filed 2024-05-09 | $3.40M derived: sum of 2 quarters · filed 2024-05-09 | $4.67M derived: sum of 3 quarters · filed 2024-05-09 | $4.76M derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | $2.73M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $4.00M derived: sum of 2 quarters · filed 2024-03-21 | $4.09M derived: sum of 3 quarters · filed 2024-03-21 | $2.01M 10-K · filed 2024-03-21 |
| 2023-09-30 | $1.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $1.37M derived: sum of 2 quarters · filed 2023-11-09 | -$717.00K 10-Q · filed 2023-11-09 | $1.26M derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-06-30 | $93.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | -$1.99M 10-Q · filed 2023-08-11 | -$17.00K derived: sum of 3 quarters · filed 2024-05-09 | $431.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-03-31 | -$2.08M 10-Q · filed 2024-05-09 | -$110.00K derived: sum of 2 quarters · filed 2024-05-09 | $338.00K derived: sum of 3 quarters · filed 2024-05-09 | -$564.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $1.97M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $2.42M derived: sum of 2 quarters · filed 2024-03-21 | $1.52M derived: sum of 3 quarters · filed 2024-03-21 | $1.50M 10-K · filed 2024-03-21 |
| 2022-09-30 | $448.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$454.00K derived: sum of 2 quarters · filed 2023-11-09 | -$472.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | -$902.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | -$920.00K 10-Q · filed 2023-08-11 | ||
| 2022-03-31 | -$18.00K 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | $1.54M 10-K · filed 2023-03-31 | |||
| 2020-12-31 | $30.59K derived: 10-K 6 month − 10-Q 3 month · filed 2021-03-29 | $422.59K 10-K · filed 2021-03-29 | ||
| 2020-09-30 | $392.00K 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |